[SCHEDULE 13G/A] Silexion Therapeutics Corp SEC Filing
Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.
Orca Capital AG ha riferito la titolarità beneficiaria di 109.432 azioni ordinarie di Silexion Therapeutics Corp, che rappresentano il 4,9% delle azioni in circolazione basato su 2.123.892 azioni in circolazione dopo l’offerta registrata dell’emittente. La comunicazione chiarisce che la persona che segnala detiene anche warrant per 153.068 azioni ordinarie ma non può esercitarli nella misura in cui farlo aumenterebbe la titolarità beneficiaria oltre il 4,99% (il “Blocco 4,99%”). Orca afferma che i titoli non sono stati acquisiti per modificare o influenzare il controllo sull’emittente e riporta potere di voto e di disposizione esclusivo sulle azioni riportate.
Orca Capital AG ha informado sobre la titularidad beneficiosa de 109.432 acciones ordinarias de Silexion Therapeutics Corp, que representan el 4,9% del total de acciones en circulación tras la emisión registrada de la emisora, con 2.123.892 acciones en circulación. La declaración aclara que la persona reportante también posee warrants para 153.068 acciones ordinarias, pero no puede ejercitarlos en la medida en que hacerlo aumentaría la titularidad beneficiosa por encima del 4,99% (el “Bloque del 4,99%”). Orca afirma que los valores no se adquirieron para cambiar o influir en el control de la emisora y reporta poder de voto y de disposición exclusivo sobre las acciones reportadas.
Orca Capital AG가 Silexion Therapeutics Corp의 109,432 보통주에 대한 실질 소유를 보고했으며, 이는 4.9%의 발행 주식 중 지분으로, 발행사의 등록 공모 이후 유통 주식 2,123,892주를 기준으로 합니다. 이 보고서는 보고자인도 153,068 주의 워런트를 보유하고 있지만, 이를 행사하면 실질 보유 지분이 4.99%를 초과하게 되므로 행사할 수 없다고 명시합니다(“4.99% 차단자”). Orca는 이 증권이 발행인의 지배권을 변경하거나 영향을 주기 위해 취득된 것이 아니며 보고된 주식에 대해 단독 의결권 및 처분권을 보유한다고 언급합니다.
Orca Capital AG a déclaré la titularité bénéficiaire de 109 432 actions ordinaires de Silexion Therapeutics Corp, représentant 4,9% des actions en circulation après l’offre enregistrée de l’émetteur, soit 2 123 892 actions en circulation. Le dépôt précise que la personne déclarant détient également des warrants pour 153 068 actions ordinaires mais ne peut les exercer dans la mesure où cela augmenterait la titularité bénéficiaire au-delà de 4,99% (le « Bloc 4,99% »). Orca indique que ces valeurs n’ont pas été acquises pour changer ou influencer le contrôle de l’émetteur et signale un pouvoir de vote et de disposition exclusif sur les actions signalées.
Orca Capital AG hat den wirtschaftlichen Eigentumsanteil an 109.432 Stammaktien von Silexion Therapeutics Corp gemeldet, was 4,9% der umlaufenden Klassenaktien entspricht, basierend auf 2.123.892 umlaufenden Aktien nach dem registrierten Angebot des Emittenten. Die Einreichung erläutert, dass die meldende Person auch Warrants für 153.068 Stammaktien hält, diese jedoch nicht ausüben kann, soweit dies die wirtschaftliche Eigentümerschaft unter 4,99% erhöhen würde (das „4,99%-Blocker“). Orca erklärt, dass die Wertpapiere nicht erworben wurden, um die Kontrolle des Emittenten zu ändern oder zu beeinflussen, und meldet alleinändige Stimmrechts- und Verfügungsgewalt über die berichteten Aktien.
Orca Capital AG أبلَغت بملكية مفيدة لــ 109,432 سهم عادي من Silexion Therapeutics Corp، تمثل 4.9% من الأسهم القائمة بناءً على 2,123,892 سهمًا قائمًا بعد عرض الإصدار المسجّل للمصدر. يوضح التقرير أن الشخص المبلغ يملك أيضاً وأوراقاً تمنح حق شراء لـ 153,068 سهمًا عاديًا، لكنه لا يمكن ممارستها لما قد يؤدي إلى رفع الملكية المفيدة فوق 4.99% (ـ“عائق 4.99%”). وتؤكد Orca أن الأوراق المالية لم تُشترَ لِتغيير أو التأثير على السيطرة على المصدر وتقر بوجود صلاحية تصويت وتصرف حصرية على الأسهم المبلَّغة.
Orca Capital AG 已报告对 109,432 股 Silexion Therapeutics Corp 的普通股享有受益所有权，占发行人登记发行后在外流通股本中的 4.9%，以 2,123,892 股在外流通股数为基准。该申报还明确，报告人同样持有 153,068 股普通股的认股权证，但在行使时不得超过使受益所有权超过 4.99% 的限额（“4.99% 阻挡区”）。Orca 表示这些证券并非为改变或影响发行人控制权而取得，并报告对所报股权拥有单独的投票权和处置权。
- Full disclosure of stake: Reports 109,432 shares, equal to 4.9% of the class, providing transparency to the market
- Clear statement of passive intent: Certification that shares were not acquired to influence control
- Warrant exercise limiter: The 4.99% Blocker prevents inadvertent crossing of the 5% threshold, reducing governance uncertainty
- Concentrated near 5% threshold: Ownership at 4.9% is close to the 5% reporting threshold, which may complicate future increases in position
- Warrants excluded from percentage: 153,068 warrants exist but are not exercisable above the blocker, limiting flexibility to increase ownership
Insights
TL;DR: A passive 4.9% stake with a strict exercise blocker limits potential control or influence.
Orca Capital AG discloses a sub-5% passive stake, which under SEC rules typically signals non-controlling intent. The separate warrant position of 153,068 shares is contractually constrained by the 4.99% blocker, preventing conversion that would push ownership above the regulatory threshold. For investors, this is a straightforward disclosure of a meaningful minority position without apparent intent to exert control; it also limits immediate upside from warrant exercise due to the blocker.
TL;DR: Filing shows compliance and clarity on voting/dispositive authority and the legal exercise limit on warrants.
The Schedule 13G/A cleanly separates sole voting and dispositive powers (both 109,432) and indicates no shared powers or group affiliations. The certification asserts passive ownership and no action to change control. The explicit 4.99% exercise restriction reduces regulatory and governance risk that might arise from sudden stake increases, but it also means potential dilution or change in influence is contractually limited.
Orca Capital AG ha riferito la titolarità beneficiaria di 109.432 azioni ordinarie di Silexion Therapeutics Corp, che rappresentano il 4,9% delle azioni in circolazione basato su 2.123.892 azioni in circolazione dopo l’offerta registrata dell’emittente. La comunicazione chiarisce che la persona che segnala detiene anche warrant per 153.068 azioni ordinarie ma non può esercitarli nella misura in cui farlo aumenterebbe la titolarità beneficiaria oltre il 4,99% (il “Blocco 4,99%”). Orca afferma che i titoli non sono stati acquisiti per modificare o influenzare il controllo sull’emittente e riporta potere di voto e di disposizione esclusivo sulle azioni riportate.
Orca Capital AG ha informado sobre la titularidad beneficiosa de 109.432 acciones ordinarias de Silexion Therapeutics Corp, que representan el 4,9% del total de acciones en circulación tras la emisión registrada de la emisora, con 2.123.892 acciones en circulación. La declaración aclara que la persona reportante también posee warrants para 153.068 acciones ordinarias, pero no puede ejercitarlos en la medida en que hacerlo aumentaría la titularidad beneficiosa por encima del 4,99% (el “Bloque del 4,99%”). Orca afirma que los valores no se adquirieron para cambiar o influir en el control de la emisora y reporta poder de voto y de disposición exclusivo sobre las acciones reportadas.
Orca Capital AG가 Silexion Therapeutics Corp의 109,432 보통주에 대한 실질 소유를 보고했으며, 이는 4.9%의 발행 주식 중 지분으로, 발행사의 등록 공모 이후 유통 주식 2,123,892주를 기준으로 합니다. 이 보고서는 보고자인도 153,068 주의 워런트를 보유하고 있지만, 이를 행사하면 실질 보유 지분이 4.99%를 초과하게 되므로 행사할 수 없다고 명시합니다(“4.99% 차단자”). Orca는 이 증권이 발행인의 지배권을 변경하거나 영향을 주기 위해 취득된 것이 아니며 보고된 주식에 대해 단독 의결권 및 처분권을 보유한다고 언급합니다.
Orca Capital AG a déclaré la titularité bénéficiaire de 109 432 actions ordinaires de Silexion Therapeutics Corp, représentant 4,9% des actions en circulation après l’offre enregistrée de l’émetteur, soit 2 123 892 actions en circulation. Le dépôt précise que la personne déclarant détient également des warrants pour 153 068 actions ordinaires mais ne peut les exercer dans la mesure où cela augmenterait la titularité bénéficiaire au-delà de 4,99% (le « Bloc 4,99% »). Orca indique que ces valeurs n’ont pas été acquises pour changer ou influencer le contrôle de l’émetteur et signale un pouvoir de vote et de disposition exclusif sur les actions signalées.
Orca Capital AG hat den wirtschaftlichen Eigentumsanteil an 109.432 Stammaktien von Silexion Therapeutics Corp gemeldet, was 4,9% der umlaufenden Klassenaktien entspricht, basierend auf 2.123.892 umlaufenden Aktien nach dem registrierten Angebot des Emittenten. Die Einreichung erläutert, dass die meldende Person auch Warrants für 153.068 Stammaktien hält, diese jedoch nicht ausüben kann, soweit dies die wirtschaftliche Eigentümerschaft unter 4,99% erhöhen würde (das „4,99%-Blocker“). Orca erklärt, dass die Wertpapiere nicht erworben wurden, um die Kontrolle des Emittenten zu ändern oder zu beeinflussen, und meldet alleinändige Stimmrechts- und Verfügungsgewalt über die berichteten Aktien.
FAQ
How many Silexion Therapeutics (SLXNW) shares does Orca Capital AG own?
Does Orca Capital have voting control over its reported SLXNW shares?
Are there warrants associated with Orca's position in Silexion?
Is Orca Capital acting to change or influence control of Silexion?
Is Orca part of a group reporting combined ownership?
